Impact of Reference and Target Region Selection on Amyloid PET SUV Ratios in the Phase 1b PRIME Study of Aducanumab

Conclusion: Dose- and time-dependent reductions in the amyloid PET SUVR were consistently observed with aducanumab only in cortical regions prone to amyloid plaque deposition, regardless of the reference region used. These data support the hypothesis that florbetapir SUVR responses associated with aducanumab treatment are a result of specific dose- and time-dependent reductions in the amyloid burden in patients with Alzheimer disease.

Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Chiao, P., Bedell, B. J., Avants, B., Zijdenbos, A. P., Grand'Maison, M., ONeill, P., OGorman, J., Chen, T., Koeppe, R. Tags: Clinical Source Type: research